Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published March 2016 | public
Journal Article

Bridged Analogues for p53-Dependent Cancer Therapy Obtained by S-Alkylation

Abstract

A small library of anticancer, cell-permeating, stapled peptides based on potent dual-specific antagonist of p53–MDM2/MDMX interactions, PMI-N8A, was synthesized, characterized and screened for anticancer activity against human colorectal cancer cell line, HCT-116. Employed synthetic modifications included: S-alkylation-based stapling, point mutations increasing hydrophobicity in key residues as well as improvement of cell-permeability by introduction of polycationic sequence(s) that were woven into the sequence of parental peptide. Selected analogue, ArB14Co, was also tested in vivo and exhibited potent anticancer bioactivity at the low dose (3.0 mg/kg). Collectively, our findings suggest that application of stapling in combination with rational design of polycationic short analogues may be a suitable approach in the development of physiologically active p53–MDM2/MDMX peptide inhibitors.

Additional Information

© 2016 Springer Netherlands. First online: 19 August 2015. This project was partially supported by funds from the Adams and Burnham endowments provided by the Dean's Office of the David Geffen School of Medicine at UCLA (PR) and the NIH/NIAID award 5U19AI067769 (EDM and WHM). Authors declare that this article content has no conflict of interest. The article does not contain any studies in patients by any of the authors. This article does not contain studies involving human subjects. All animal experiments were approved by the UCLA Animal Care and Use Committee and conformed to local and national guidelines.

Additional details

Created:
August 20, 2023
Modified:
October 18, 2023